D-0146-2018 Class III Terminated

Recalled by Taro Pharmaceuticals U.S.A., Inc. — Hawthorne, NY

FDA drug recall D-0146-2018 was initiated by Taro Pharmaceuticals U.S.A., Inc. on Sep 20, 2017 and is designated Class III. Reason for recall: Cross contamination with other products: traces of Dapsone were found in the finished product. The recall status is terminated (terminated Sep 10, 2020). Affected quantity: 16,944 tubes.

Recall details

Product Type
Drugs
Report Date
Nov 1, 2017
Initiation Date
Sep 20, 2017
Termination Date
Sep 10, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
16,944 tubes

Product description

Fluocinonide Gel USP, 0.05%, 15 g tube, Rx Only, Mfd. by: Taro Pharmaceuticals Inc. Brampton Ontario Canada L6T1C1, Dist. by: Taro Pharmaceuticals U.S.A . Inc. Hawthorne NY 10532, NDC 51672-1279-1

Reason for recall

Cross contamination with other products: traces of Dapsone were found in the finished product.

Distribution pattern

Nationwide

Code information

Lot #: A771026850, Exp 6/18

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0146-2018
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0146-2018. Report a data issue: hello@regdatalab.com.